We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Drug Products » FDA Adverse Event Reporting System (FAERS) – Webinar Recording/Transcript

Other Options

USB Audio Recording/Transcript - Dec. 18, 2019

$287.00

USB Audio Recording/Transcript - Dec. 18, 2019

$258.00

USB Audio Recording/Transcript - Dec. 18, 2019

$244.00

USB Audio Recording/Transcript - Dec. 18, 2019

$230.00

USB Audio Recording/Transcript - Dec. 18, 2019

$215.00
webinar recording

FDA Adverse Event Reporting System (FAERS) – Webinar Recording/Transcript

$287.00
Drug Products

Product Details

FDA Adverse Event Reporting System (FAERS): Practical Insights to Avoid 483s

FDA’s increasing scrutiny of postmarket data means the agency is looking to industry to provide transparency into the impact of their drug products on patients.

Do you know how to avoid the pitfalls?

Fail to properly identify and report an adverse event with FDA’s Adverse Event Reporting System (FAERS) and you get a 483. Fail to report within the required time frame and you get another.

Beyond the regulatory compliance ramifications, the newly publicly available FAERS dashboard — openFDA — provides exposure to your reported events and can influence choices by healthcare providers and patients alike when it comes to choosing your therapeutic product.

Ricki Chase, M.S., Executive Director at Lachman Consultant Services and a former FDA investigator, explains how you can avoid 483s — among other serious issues.

Presentation Takeaways:

  • The difference between serious unexpected and serious expected events
  • The reportability time frame, when the clock starts and how to avoid being a late filer
  • Common FDA 483 observations related to adverse events and how to avoid them in your organization
  • What not to report under the FAERS program
  • How to handle combination product reporting
  • The value of data, how to access data and what it reveals or means

Ensure your company’s compliance by avoiding FAERS-related 483s.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing